14-Azacamptothecin: A potent water-soluble topoisomerase I poison

Journal of the American Chemical Society

Volumn 127, Issue 3, 2005, Pages 838-839

  Cheng, Kejun ^a   Rahier, Nicolas J ^a   Eisenhauer, Brian M ^a   Gao, Rong ^a   Thomas, S J ^a   Hecht, Sidney M ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

14 AZACAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; DNA TOPOISOMERASE; LUOTONIN A; PYRROLOQUINAZOLINOQUINOLINE ALKALOID; ROSETTACIN; UNCLASSIFIED DRUG;

ARTICLE; CELL DEATH; COVALENT BOND; CRYSTAL STRUCTURE; CYTOTOXICITY; DNA CLEAVAGE; DNA PROTEIN COMPLEX; DRUG POTENCY; DRUG SOLUBILITY; DRUG STRUCTURE; GENE; GENE EXPRESSION; IC 50; PROTEIN BINDING; PROTEIN DNA INTERACTION; PROTEIN EXPRESSION; PROTEIN STRUCTURE; STEREOCHEMISTRY; STRUCTURE ANALYSIS; TOPOISOMERASE I GENE; X RAY CRYSTALLOGRAPHY; YEAST;

CAMPTOTHECIN; DNA TOPOISOMERASES, TYPE I; ENZYME INHIBITORS; HUMANS; KINETICS; PYRROLES; QUINONES; SOLUBILITY; WATER;

EID: 12444272662     PISSN: 00027863     EISSN: None     Source Type: Journal    
DOI: 10.1021/ja0442769     Document Type: Article

References (26)

1. Wall, M. E.; Wani, M. C.; Cook, C. E.; Palmer, K. H.; McPhail, A. T.; Sim, G. A. J. Am. Chem. Soc. 1966, 88, 3888.
2. (a) Hsiang, Y.-H.; Hertzberg, R.; Hecht, S. M.; Liu, L. F. J. Biol. Chem. 1985, 260, 14873.
3. (b) Kohn, K. W.; Pommier, Y. Ann. N.Y. Acad. Sci. 2000, 922, 11.
4. Hsiang, Y.-H., Lihou, M. G.; Liu, L. F. Cancer Res. 1989, 49, 5077.
5. (a) Moertel, C. G.; Schutt, A. J.; Reitemeier, R. J.; Hahn, R. G. Cancer Chemother. Rep. 1972, 56, 95.
6. (b) Gottlieb, J. A.; Luce, J. K. Cancer Chemother. Rep. 1972, 56, 103.
7. (a) Takimoto, C. H.; Wright, J.; Arbuck, S. G. Biochim. Biophys. Acta 1998, 1400, 107.
8. (b) O'Leary, J.; Muggia, F. M. Eur. J. Cancer 1998, 34, 1500.
9. (c) Saltz, L. B.; Cox, J. V.; Blanke, C.; Rosen, L. S.; Fehrenbacher, L.; Moore, M. J.; Maroun, J. A.; Ackland, S. P.; Locker, P. K.; Pirotta, N.; Elfring, G. L.; Miller, L. L. N. Eng. J. Med. 2000, 343, 905.
10. (d) Ozols, R. F. Int. J. Gynecol. Cancer 2000, 10, 33.
11. (e) Vanhoefer, U.; Harstrick, A.; Achterrath, W.; Cao, S.; Seeber, S.; Rustum, Y. M. J. Clin. Oncol. 2001, 19, 1501.
12. (f) Ulukan, H.; Swaan, P. W. Drugs 2002, 62, 2039.
13. (g) Garcia-Carbonero, R.; Supko, J. G. Clin. Cancer Res. 2002. 5, 641.
14. Cagir, A.; Jones, S. H.; Gao, R.; Eisenhauer, B. M.; Hecht, S. M. J. Am. Chem. Soc. 2003, 125, 13628.
15. (a) Hutchinson, C. R. Tetrahedron 1981, 37, 1047.
16. (b) Hertzberg, R. P.; Caranfa, M. J.; Holden, K. G.; Jakas, D. R.; Gallagher, G.; Mattern, M. R.; Mong, S.-M.; Bartus, J. O.; Johnson, R. K.; Kingsbury, W. D. J. Med Chem. 1989, 32, 715.
17. (a) Cagir, A.; Jones, S. H.; Eisenhauer, B. M.; Gao, R.; Hecht, S. M. Bioorg. Med. Chem. Lett. 2004. 14, 2051.
18. (b) Cagir, A.; Eisenhauer, B. M.; Gao, R.; Thomas, S. J.; Hecht, S. M. Bioorg. Med. Chem. 2004, 12, 6287.
19. Fox, B. M.; Xiao, X.; Antony, S.; Kohlhagen, G.; Pommier, Y.; Staker, B. L.; Stewart, L.; Cushman, M. J. Med. Chem. 2003, 46, 3275.
20. We have denoted compound 3 rosettacin, after the Rosetta stone used to decode Egyptian hieroglyphics for the first time.
21. Bjornsti, M. A.; Benedetti, P.; Viglianti, G. A.; Wang, J. C. Cancer Res. 1989, 49, 6318.
22. Staker, B. L.; Hjerrild, K.; Feese, M. D.; Behnke, C. A.; Burgin, A. B., Jr.; Stewart, L. Proc. Natl. Acad. U.S.A. 2002, 99, 15387.
23. The synthesis of 4 will be reported elsewhere. Rahier, N. J.; Cheng, K.; Gao, R.; Eisenhauer, B. M.; Hecht, S. M. manuscript in preparation. Samples of 4 used for assay were shown by HPLC to be predominantly in the lactone form.
24. The high concentrations of CPTs employed for inhibition of DNA relaxation are not relevant physiologically, but the greater potency of 14-aza CPT is significant mechanistically.
25. (a) Wang, X.; Wang, L.-K.; Kingsbury, W. D.; Johnson, R. K.; Hecht, S. M. Biochemistry 1998, 37, 9399.
26. (b) Wang, X.; Zhou, X.; Hecht, S. M. Biochemistry 1999, 38, 4374.